Liquid Biopsy Markets: Global Analysis and Opportunity Evaluation 2016 - 2020

 
Customer Support
+44 (0)1487 843 722

If you have any questions regarding this
report, please call us on the number above.

Chat with the Author
Call +44 (0)7870 204 848
 
Untitled Document

INDEX

CHAPTER 1. BACKGROUND (p22)

1.1. This Chapter
1.2. Background
1.3. Study Questions

CHAPTER 2. STUDY PARTICIPANTS (p52)

2.1. This Chapter
2.2. Global Regions

Figure 2.1. Global regions of participants in CircBio 2015
Table 2.1. Global regions of participants in CircBio 2015
Figure 2.2. Global regions of participants inCircBio 2015 (Study 1)
Table 2.2. Global regions of participants inCircBio 2015 (Study 1)

2.3. Countries

Figure 2.3. Top ten countries of participants in CircBio 2015
Table 2.3. Countries of participants in CircBio 2015
Figure 2.4. Top ten countries of participants inCircBio 2015 (Study 1)
Table 2.4. Countries of participants inCircBio 2015 (Study 1)

2.4. Organisation Types

Figure 2.5. Organisation types of participants in CircBio 2015
Table 2.5. Organisation types of participants in CircBio 2015
Figure 2.6. Organisation types of participants inCircBio 2015 (Study 1)
Table 2.6. Organisation types of participants inCircBio 2015 (Study 1)

2.5. Role

Figure 2.7. Roles of participants in CircBio 2015
Table 2.7. Roles of participants in CircBio 2015
Figure 2.8. Roles of participants in CircBio 2015 (Study 1)
Table 2.8. Roles of participants in CircBio 2015 (Study 1)

2.6. Experience

Figure 2.9. Top ten experience levels of participants in CircBio 2015
Table 2.9. Experience of participants in CircBio 2015
Figure 2.10. Top ten experience levels of participants in CircBio 2015 (Study 1)
Table 2.10. Experience of participants in CircBio 2015 (Study 1)

2.7 Discussion

CHAPTER 3. AREA OF WORK (p51)

3.1. This Chapter
3.2. Area of Work

Figure 3.1. Area of work of participants in CircBio 2015 participants
Table 3.1. Area of work of participants in CircBio 2015 participants
Figure 3.2. Area of work of participants in CircBio 2015 participants (Study 1)
Table 3.2. Area of work of participants in CircBio 2015 participants (Study 1)

CHAPTER 4. CIRCULATING TUMOUR CELLS (p60)

4.1. This Chapter
4.2. Role of Participant

Figure 4.1. Role ofCircBio 2015 participants in the cancer field, who study CTCs in their work.
Table 4.1. Role ofCircBio 2015 participants in the cancer field, who study CTCs in their work.
Figure 4.2. Role ofCircBio 2015 participants in the cancer field, who study CTCs in their work (Study 1)
Table 4.2. Role ofCircBio 2015 participants in the cancer field, who study CTCs in their work (Study 1)

4.3. Current Purposes

Figure 4.3. Top ten current main purpose(s) of their work, relating to CTCs, ofCircBio 2015 participants
Table 4.3. Current main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants
Figure 4.4. Top ten current main purpose(s) of their work, relating to CTCs, ofCircBio 2015 participants (Study 1)
Table 4.4. Current main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants (Study 1)

4.4. Future Purposes

Figure 4.5. Top ten future main purpose(s) of their work, relating to CTCs, ofCircBio 2015 participants
Table 4.5. Future main purpose(s) of their work, relating to CTCs, ofCircBio 2015 participants
Figure 4.6. Top ten future main purpose(s) of their work, relating to CTCs, ofCircBio 2015 participants (Study 1)
Table 4.6. Future main purpose(s) of their work, relating to CTCs, ofCircBio 2015 participants (Study 1)

4.5. Current Cancers

Figure 4.7. Top ten current cancers investigated in their work, relating to CTCs, ofCircBio 2015 participants
Table 4.7. Current cancers investigated in their work, relating to CTCs, ofCircBio 2015 participants
Figure 4.8. Top ten current cancers investigated in their work, relating to CTCs, ofCircBio 2015 participants (Study 1)
Table 4.8. Current cancers investigated in their work, relating to CTCs, ofCircBio 2015 participants (Study 1)

4.6. Future Cancer

Figure 4.9. Top ten future cancers investigated in their work, relating to CTCs, ofCircBio 2015 participants
Table 4.9. Future cancers investigated in their work, relating to CTCs, of CircBio 2015 participants
Figure 4.10. Top ten future cancers investigated in their work, relating to CTCs, ofCircBio 2015 participants (Study 1)
Table 4.10. Future cancers investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)

4.7. Current Samples

igure 4.11. Top ten current sample types investigated in their work, relating to CTCs, of CircBio 2015 participants
Table 4.11. Current sample types investigated in their work, relating to CTCs, of CircBio 2015 participants
Figure 4.12. Top ten current sample types investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)
Table 4.12. Current sample types investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)

4.8. Future Samples

Figure 4.13. Top ten future sample types investigated in their work, relating to CTCs, of CircBio 2015 participants
Table 4.13. Future sample types investigated in their work, relating to CTCs, of CircBio 2015 participants
Figure 4.14. Top ten future sample types investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)
Table 4.14. Future sample types investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)

4.9. Study of CTC Sub-Populations

Figure 4.15.CircBio 2015 participants' study of CTC sub-populations in their CTC work
Table 4.15.CircBio 2015 participants' study of CTC sub-populations in their CTC work
Figure 4.16.CircBio 2015 participants' study of CTC sub-populations in their CTC work (Study 1)
Table 4.16.CircBio 2015 participants' study of CTC sub-populations in their CTC work (Study 1)

4.10. Current CTC Sub-Populations

Figure 4.17. Top ten current CTC subpopulations studied, for thoseCircBio 2015 participants who answered 'yes' to the previous question
Table 4.17. Current CTC subpopulations studied, for thoseCircBio 2015 participants who answered 'yes' to the previous question
Figure 4.18. Top ten current CTC subpopulations studied, for thoseCircBio 2015 participants who answered 'yes' to the previous question (Study 1)
Table 4.18. Current CTC subpopulations studied, for thoseCircBio 2015 participants who answered 'yes' to the previous question (Study 1)

4.11. Future CTC Sub-Populations

Figure 4.19. Top ten future anticipated CTC subpopulations to be studied, by thoseCircBio 2015 participants who answered 'yes' to the previous question
Table 4.19. Future CTC subpopulations anticipated studied, by thoseCircBio 2015 participants who answered 'yes' to the previous question
Figure 4.20. Top ten future anticipated CTC subpopulations to be studied, by thoseCircBio 2015 participants who answered 'yes' to the previous question (Study 1)
Table 4.20. Future CTC subpopulations anticipated studied, by thoseCircBio 2015 participants who answered 'yes' to the previous question (Study 1)

4.12. Future Study of CTC Sub-Populations

Figure 4.21. The future anticipated study of CTC subpopulations, by thoseCircBio 2015 participants who answered 'No' to the previous question (see sections 4.10)
Table 4.21. The future anticipated study of CTC subpopulations, by thoseCircBio 2015 participants who answered 'No' to the previous question (see sections 4.10)
Figure 4.22. The future anticipated study of CTC subpopulations, by thoseCircBio 2015 participants who answered 'No' to the previous question (see sections 4.10) (Study 1)
Table 4.22. The future anticipated study of CTC subpopulations, by thoseCircBio 2015 participants who answered 'No' to the previous question (see sections 4.10) (Study 1)

4.13. Current CTC Measurements

Figure 4.23. Current CTC measurements used byCircBio 2015 participants, in their CTC studies
Table 4.23. Current CTC measurements used byCircBio 2015 participants, in their CTC studies
Figure 4.24. Current CTC measurements used byCircBio 2015 participants, in their CTC studies (Study 1)
Table 4.24. Current CTC measurements used byCircBio 2015 participants, in their CTC studies (Study 1)

4.14. Future CTC Measurements

Figure 4.25. Future anticipated CTC measurements ofCircBio 2015 participants, in their CTC studies.
Table 4.25. Future anticipated CTC measurements ofCircBio 2015 participants, in their CTC studies.
Figure 4.26. Future anticipated CTC measurements ofCircBio 2015 participants, in their CTC studies (Study 1)
Table 4.26. Future anticipated CTC measurements ofCircBio 2015 participants, in their CTC studies (Study 1)

4.15. Current CTC Markers

Figure 4.27. Top ten current CTC markers studied byCircBio 2015 participants, in their CTC studies
Table 4.27. Current CTC markers studied byCircBio 2015 participants, in their CTC studies
Figure 4.28. Top ten current CTC markers studied byCircBio 2015 participants, in their CTC studies (Study 1)
Table 4.28. Current CTC markers studied byCircBio 2015 participants, in their CTC studies (Study 1)

4.16. Future CTC Markers

Figure 4.29. Top ten future CTC markers anticipated to be studied byCircBio 2015 participants, in their CTC studies
Table 4.29. Future CTC markers anticipated to be studied byCircBio 2015 participants, in their CTC studies
Figure 4.30. Top ten future CTC markers anticipated to be studied byCircBio 2015 participants, in their CTC studies (Study 1)
Table 4.30. Future CTC markers anticipated to be studied byCircBio 2015 participants, in their CTC studies (Study 1)

4.17. Current CTC Enrichment, Isolation or Detection Methods

Figure 4.31. Top ten current CTC enrichment, isolation or detection methods used byCircBio 2015 participants, in their CTC studies
Table 4.31. Current CTC enrichment, isolation or detection methods used byCircBio 2015 participants, in their CTC studies
Figure 4.32. Top ten current CTC enrichment, isolation or detection methods used byCircBio 2015 participants, in their CTC studies (Study 1)
Table 4.32. Current CTC enrichment, isolation or detection methods used byCircBio 2015 participants, in their CTC studies (Study 1)

4.18. Current CTC Enrichment, Isolation or Detection Methods

Figure 4.33. Top ten current CTC enrichment, isolation or detection methods used by CTC cfDNA-RNA 2015 participants, in their CTC studies
Table 4.33. Current CTC enrichment, isolation or detection methods used by CTC cfDNA-RNA 2015 participants, in their CTC studies
Figure 4.34. Top ten current CTC enrichment, isolation or detection methods used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)
Table 4.34. Current CTC enrichment, isolation or detection methods used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.19. Future CTC Enrichment, Isolation or Detection Methods

Figure 4.35. Top ten future CTC enrichment, isolation or detection methods anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies
Table 4.35. Future CTC enrichment, isolation or detection methods anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies
Figure 4.36. Top ten future CTC enrichment, isolation or detection methods anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)
Table 4.36. Future CTC enrichment, isolation or detection methods anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.20. Current Non-Molecular Techniques

Figure 4.37. Top ten current non-molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies
Table 4.37. Current non-molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies
Figure 4.38. Top ten current non-molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)
Table 4.38. Current non-molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.21. Future Non-Molecular Techniques

Figure 4.39. Top ten future non-molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies
Table 4.39. Future non-molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies
Figure 4.40. Top ten future non-molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)
Table 4.40. Future non-molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.22. Current Molecular Techniques

Figure 4.41. Top ten current molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies
Table 4.42. Current molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies
Figure 4.42. Top ten current molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)
Table 4.42. Current molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.23. Future Molecular Techniques

Figure 4.43. Top ten future molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies
Table 4.43. Future molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies
Figure 4.44. Top ten future molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)
Table 4.44. Future molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.24. Current Molecular Suppliers

Figure 4.45. Top ten current main suppliers of molecular products (systems, kits, reagents) relating to
Table 4.45. Current main suppliers of molecular products (systems, kits, reagents) relating to
Figure 4.46. Top ten current main suppliers of molecular products (systems, kits, reagents) relating to (Study 1)
Table 4.46. Current main suppliers of molecular products (systems, kits, reagents) relating to (Study 1)

4.25. Future Molecular Suppliers

Figure 4.47. Top ten future main suppliers of molecular products (systems, kits, reagents), anticipated by
Table 4.47. Future main suppliers of molecular products (systems, kits, reagents), anticipated by
Figure 4.48. Top ten future main suppliers of molecular products (systems, kits, reagents), anticipated by (Study 1)
Table 4.48. Future main suppliers of molecular products (systems, kits, reagents), anticipated by (Study 1)

4.26. Current Nucleic Acid Forms

Figure 4.49. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their CTC studies
Table 4.49. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their CTC studies
Figure 4.50. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)
Table 4.50. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.27. Future Nucleic Acid Forms

Figure 4.51. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies
Table 4.51. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies
Figure 4.52. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)
Table 4.52. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.28. Current CTC Molecular Biomarkers

Figure 4.53. Top ten current CTC molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their CTC studies
Table 4.53. Current CTC molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their CTC studies
Figure 4.54. Top ten current CTC molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their CTC studies (Study 1)
Table 4.54. Current CTC molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their CTC studies (Study 1)

4.29. Future CTC Molecular Biomarkers

Figure 4.55. Top ten future CTC molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their CTC studies
Table 4.55. Future CTC molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their CTC studies
Figure 4.56. Top ten future CTC molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their CTC studies (Study 1)
Table 4.56. Future CTC molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their CTC studies (Study 1)

4.30. Clinical Utilities

Figure 4.57. Top ten clinical utilities of studying CTCs, indicated by participants in CTC cfDNA-RNA 2015
Table 4.57. Clinical utilities of studying CTCs, indicated by participants in CTC cfDNA-RNA 2015
Figure 4.58. Top ten clinical utilities of studying CTCs, indicated by participants in CTC cfDNA-RNA 2015 (Study 1)
Table 4.58. Clinical utilities of studying CTCs, indicated by participants in CTC cfDNA-RNA 2015 (Study 1)

4.31. Recent CTC Trends

Figure 4.59. Top ten recent trends in the number of CTC tests (% increase or % decrease). Indicated by CTC cfDNA-RNA 2015 participants
Table 4.59. Recent trends in the number of CTC tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants
Figure 4.60. Top ten recent trends in the number of CTC tests (% increase or % decrease). Indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 4.60. Recent trends in the number of CTC tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants (Study 1)

4.32. Future CTC Trends

Figure 4.61. Top ten future trends in the number of CTC tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants
Table 4.61. Future trends in the number of CTC tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants
Figure 4.62. Top ten future trends in the number of CTC tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 4.62. Future trends in the number of CTC tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants (Study 1)

4.33. CTC Limitations
Figure 4.63. Top ten limitations in the study of CTCs, indicated by CTC cfDNA-RNA 2015 participants
Table 4.63. Limitations in the study of CTCs, indicated by CTC cfDNA-RNA 2015 participants
Figure 4.64. Top ten limitations in the study of CTCs, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 4.64. Limitations in the study of CTCs, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

4.34. Costs

Figure 4.65. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for CTC tests, indicated by CTC cfDNA-RNA 2015 participants
Table 4.65. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for CTC tests, indicated by CTC cfDNA-RNA 2015 participants
Figure 4.66. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for CTC tests, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 4.66. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for CTC tests, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

4.35. CTCs in Drug R&D

Figure 4.67. Use of CTCs in drug R&D, indicated by CTC cfDNA-RNA 2015 participants
Table 4.67. Use of CTCs in drug R&D, indicated by CTC cfDNA-RNA 2015 participants
Figure 4.68. Use of CTCs in drug R&D, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 4.68. Use of CTCs in drug R&D, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

4.36. CTCs and Drug R&D Development Phase
Figure 4.69. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 4.29)
Table 4.69. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 4.29)
Figure 4.70. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 4.29) (Study 1)
Table 4.70. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 4.29) (Study 1)

4.37. Future use of CTCs in Drug R&D

Figure 4.71. Future use of CTCs in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 4.29)
Table 4.71. Future use of CTCs in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 4.29)
Figure 4.72. Future use of CTCs in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 4.29) (Study 1)
Table 4.72. Future use of CTCs in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 4.29) (Study 1)

4.38. CTCs in Companion Diagnostics
Figure 4.73. The use of CTCs in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants
Table 4.73. The use of CTCs in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants
Figure 4.74. The use of CTCs in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 4.74. The use of CTCs in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

4.39. CTCs in Future Companion Diagnostics

Figure 4.75. The future use of CTCs in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants
Table 4.75. The future use of CTCs in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants
Figure 4.76. The future use of CTCs in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 4.76. The future use of CTCs in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (Study 1)

CHAPTER 5 CIRCULATING CELL-FREE DNA AND RNA (cfDNA and cfRNA) (p192)

5.1. This Chapter
5.2. Role of Participant

Figure 5.1. Role of CTC cfDNA-RNA 2015 participants in the cancer field, who study cfDNA and/or cfRNA in their work.
Table 5.1. Role of CTC cfDNA-RNA 2015 participants in the cancer field, who study cfDNA and/or cfRNA. In their work.
Figure 5.2. Role of CTC cfDNA-RNA 2015 participants in the cancer field, who study cfDNA and/or cfRNA in their work (Study 1)
Table 5.2. Role of CTC cfDNA-RNA 2015 participants in the cancer field, who study cfDNA and/or cfRNA. In their work (Study 1)

5.3. Current Purpose

Figure 5.3. Participant's top ten current purposes of the study of cfDNA or cfRNA in their work.
Table 5.3. Participant's current purposes of the study of cfDNA or cfRNA in their work.
Figure 5.4. Participant's top ten current purposes of the study of cfDNA or cfRNA in their work (Study 1)
Table 5.4. Participant's current purposes of the study of cfDNA or cfRNA in their work (Study 1)

5.4. Future Purpose

Figure 5.5. The top ten future anticipated purposes of the study of cfDNA or cfRNA in their work.
Table 5.5. The future anticipated purposes of the study of cfDNA or cfRNA in their work.
Figure 5.6. The top ten future anticipated purposes of the study of cfDNA or cfRNA in their work (Study 1)
Table 5.6. The future anticipated purposes of the study of cfDNA or cfRNA in their work (Study 1)

5.5. Current Diseases

Figure 5.7. Top ten current diseases to which participant's cfDNA or cfRNA studies relate.
Table 5.7. Current diseases to which participant's cfDNA or cfRNA studies relate.
Figure 5.8. Top ten current diseases to which participant's cfDNA or cfRNA studies relate (Study 1)
Table 5.8. Current diseases to which participant's cfDNA or cfRNA studies relate (Study 1)

5.6. Future Diseases

Figure 5.9. Top ten anticipated future diseases to which participant's cfDNA or cfRNA studies relate
Table 5.9. Anticipated future diseases to which participant's cfDNA or cfRNA studies relate
Figure 5.10. Top ten anticipated future diseases to which participant's cfDNA or cfRNA studies relate (Study 1)
Table 5.10. Anticipated future diseases to which participant's cfDNA or cfRNA studies relate (Study 1)

5.7. Current Cancers

Figure 5.11. Top ten current cancers to which participant's cfDNA or cfRNA studies relate.
Table 5.11. Current cancers to which participant's cfDNA or cfRNA studies relate.
Figure 5.12. Top ten current cancers to which participant's cfDNA or cfRNA studies relate (Study 1)
Table 5.12. Current cancers to which participant's cfDNA or cfRNA studies relate (Study 1)

5.8. Future Cancers

Figure 5.13. Top ten anticipated future cancers to which participant's cfDNA or cfRNA studies relate
Table 5.13. Anticipated future cancers to which participant's cfDNA or cfRNA studies relate
Figure 5.14. Top ten anticipated future cancers to which participant's cfDNA or cfRNA studies relate (Study 1)
Table 5.14. Anticipated future cancers to which participant's cfDNA or cfRNA studies relate (Study 1)

5.9. Current Sample Types

Figure 5.15. Top ten current sample types to which participant's cfDNA or cfRNA studies relate.
Table 5.15. Current sample types to which participant's cfDNA or cfRNA studies relate.
Figure 5.16. Top ten current sample types to which participant's cfDNA or cfRNA studies relate (Study 1)
Table 5.16. Current sample types to which participant's cfDNA or cfRNA studies relate (Study 1)

5.10. Future Sample Types

Figure 5.17. Top ten anticipated future sample types to which participant's cfDNA or cfRNA studies relate
Table 5.17. Anticipated future sample types to which participant's cfDNA or cfRNA studies relate
Figure 5.18. Top ten anticipated future sample types to which participant's cfDNA or cfRNA studies relate (Study 1)
Table 5.18. Anticipated future sample types to which participant's cfDNA or cfRNA studies relate (Study 1)

5.11. Current Molecular Techniques

Figure 5.19. Top ten current molecular techniques to which participant's cfDNA or cfRNA studies relate.
Table 5.19. Current molecular techniques to which participant's cfDNA or cfRNA studies relate
Figure 5.20. Top ten current molecular techniques to which participant's cfDNA or cfRNA studies relate (Study 1)
Table 5.20. Current molecular techniques to which participant's cfDNA or cfRNA studies relate (Study 1)

5.12. Future Molecular Techniques

Figure 5.21. Top ten anticipated future molecular techniques to which participant's cfDNA or cfRNA studies relate
Table 5.21. Anticipated future molecular techniques to which participant's cfDNA or cfRNA studies relate
Figure 5.22. Top ten anticipated future molecular techniques to which participant's cfDNA or cfRNA studies relate (Study 1)
Table 5.22. Anticipated future molecular techniques to which participant's cfDNA or cfRNA studies relate (Study 1)

5.13. Current Molecular Suppliers

Figure 5.23. Top ten current main suppliers of molecular products (systems, kits, reagents) relating to
Table 5.23. Current main suppliers of molecular products (systems, kits, reagents) relating to
Figure 5.24. Top ten current main suppliers of molecular products (systems, kits, reagents) relating to (Study 1)
Table 5.24. Current main suppliers of molecular products (systems, kits, reagents) relating to (Study 1)

5.14. Future Molecular Suppliers

Figure 5.25. Top ten future main suppliers of molecular products (systems, kits, reagents), anticipated by
Table 5.25. Future main suppliers of molecular products (systems, kits, reagents), anticipated by
Figure 5.26. Top ten future main suppliers of molecular products (systems, kits, reagents), anticipated by (Study 1)
Table 5.26. Future main suppliers of molecular products (systems, kits, reagents), anticipated by (Study 1)

5.15. Enrichment or Isolation

5.16. Current Nucleic Acid Forms

Figure 5.27. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies
Table 5.27. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies
Figure 5.28. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies (Study 1)
Table 5.28. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies (Study 1)

5.17. Future Nucleic Acid Forms

Figure 5.29. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies
Table 5.29. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies
Figure 5.30. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies (Study 1)
Table 5.30. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies (Study 1)

5.18. Current cfDNA and/or cfRNA Molecular Biomarkers

Figure 5.31. Top ten current cfDNA and/or cfRNA molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies
Table 5.31. Current cfDNA and/or cfRNA molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies
Figure 5.32. Top ten current cfDNA and/or cfRNA molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies (Study 1)
Table 5.32. Current cfDNA and/or cfRNA molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies (Study 1)

5.19. Future cfDNA and/or cfRNA Molecular Biomarkers

Figure 5.33. Top ten future cfDNA and/or cfRNA molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies
Table 5.33. Future cfDNA and/or cfRNA molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies
Figure 5.34. Top ten future cfDNA and/or cfRNA molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies (Study 1)
Table 5.34. Future cfDNA and/or cfRNA molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies (Study 1)

5.20. Clinical Utilities

Figure 5.35. Top ten clinical utilities of studying cfDNA and/or cfRNA, indicated by participants in CTC cfDNA-RNA 2015
Table 5.35. Clinical utilities of studying cfDNA and/or cfRNA, indicated by participants in CTC cfDNA-RNA 2015
Figure 5.36. Top ten clinical utilities of studying cfDNA and/or cfRNA, indicated by participants in CTC cfDNA-RNA 2015 (Study 1)
Table 5.36. Clinical utilities of studying cfDNA and/or cfRNA, indicated by participants in CTC cfDNA-RNA 2015 (Study 1)

5.21. Recent cfDNA and/or cfRNA Trends

Figure 5.37. Top ten recent trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants
Table 5.37. Recent trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants
Figure 5.38. Top ten recent trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 5.38. Recent trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.22. Future cfDNA and/or cfRNA Trends

Figure 5.39. Top ten future trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants
Table 5.39. Future trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants
Figure 5.40. Top ten future trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 5.40. Future trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants (Study 1)

5.23. cfDNA and/or cfRNA Limitations

Figure 5.41. Top ten limitations in the study of cfDNA and/or cfRNA, indicated by CTC cfDNA-RNA 2015 participants
Table 5.41. Limitations in the study of cfDNA and/or cfRNA, indicated by CTC cfDNA-RNA 2015 participants
Figure 5.42. Top ten limitations in the study of cfDNA and/or cfRNA, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 5.42. Limitations in the study of cfDNA and/or cfRNA, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.24. Costs

Figure 5.43. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for cfDNA and/or cfRNA tests, indicated by CTC cfDNA-RNA 2015 participants
Table 5.43. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for cfDNA and/or cfRNA tests, indicated by CTC cfDNA-RNA 2015 participants
Figure 5.44. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for cfDNA and/or cfRNA tests, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 5.44. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for cfDNA and/or cfRNA tests, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.25. cfDNA and/or cfRNA in Drug R&D

Figure 5.45. Use of cfDNA and/or cfRNA in drug R&D, indicated by CTC cfDNA-RNA 2015 participants
Table 5.45. Use of cfDNA and/or cfRNA in drug R&D, indicated by CTC cfDNA-RNA 2015 participants
Figure 5.46. Use of cfDNA and/or cfRNA in drug R&D, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 5.46. Use of cfDNA and/or cfRNA in drug R&D, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.26. cfDNA and/or cfRNA and Drug R&D Development Phase

Figure 5.47. Use of cfDNA and/or cfRNA in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 5.27)
Table 5.47. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 5.27)
Figure 5.48. Use of cfDNA and/or cfRNA in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 5.27) (Study 1)
Table 5.48. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 5.27) (Study 1)

5.27. Future use of cfDNA and/or cfRNA in Drug R&D

Figure 5.49. Future use of cfDNA and/or cfRNA in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 5.27)
Table 5.49. Future use of cfDNA and/or cfRNA in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 5.27)
Figure 5.50. Future use of cfDNA and/or cfRNA in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 5.27) (Study 1)
Table 5.50. Future use of cfDNA and/or cfRNA in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 5.27) (Study 1)

5.28. cfDNA and/or cfRNA in Companion Diagnostics

Figure 5.51. The use of cfDNA and/or cfRNA in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants
Table 5.51. The use of cfDNA and/or cfRNA in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants
Figure 5.52. The use of cfDNA and/or cfRNA in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 5.52. The use of cfDNA and/or cfRNA in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.29. cfDNA and/or cfRNA in Future Companion Diagnostics

Figure 5.53. The future use of cfDNA and/or cfRNA in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous questions (see 5.30)
Table 5.53. The future use of cfDNA and/or cfRNA in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous questions (see 5.30)
Figure 5.54. The future use of cfDNA and/or cfRNA in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous questions (see 5.30) (Study 1)
Table 5.54. The future use of cfDNA and/or cfRNA in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous questions (see 5.30) (Study 1)

CHAPTER 6 EXOSOMES (p279)

6.1. This Chapter

6.2. Current study of Exosomes

Figure 6.1. The study of exosomes by CTC cfDNA-RNA 2015 participants
Table 6.1. The study of exosomes by CTC cfDNA-RNA 2015 participants
Figure 6.2. The study of exosomes by CTC cfDNA-RNA 2015 participants (Study 1)
Table 6.2. The study of exosomes by CTC cfDNA-RNA 2015 participants (Study 1)

6.3. Future study of Exosomes

Figure 6.3. The future study of exosomes, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous question, see 6.3).
Table 6.3. The future study of exosomes, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous question, see 6.3).
Figure 6.4. The future study of exosomes, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous question, see 6.3) (Study 1)
Table 6.4. The future study of exosomes, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous question, see 6.3) (Study 1)

6.4. Disease Areas

Figure 6.5. Disease areas of of CTC cfDNA-RNA 2015 participants, to which their exosome studies relate
Table 6.5. Disease areas of of CTC cfDNA-RNA 2015 participants, to which their exosome studies relate
Figure 6.6. Disease areas of of CTC cfDNA-RNA 2015 participants, to which their exosome studies relate (Study 1)
Table 6.6. Disease areas of of CTC cfDNA-RNA 2015 participants, to which their exosome studies relate (Study 1)

6.5. Isolation of Exosomes

CHAPTER 7 CLINICAL TRIALS (p320)

7.1. This Chapter

7.2. Clinical Trials

Figure 7.1. Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA
Table 7.1. Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA
Figure 7.2. CTC or cfDNA/cfRNA Clinical Trials by Recruitment Stage
Table 7.2. CTC or cfDNA/cfRNA Clinical Trials by Recruitment Stage

7.3. CTC vs. Circulating Cell-Free Nucleic Acids (cfDNA and cfRNA)

Figure 7.3. CTCs Vs. cfDNA/cfRNA in Clinical Trials
Table 7.3. CTCs Vs. cfDNA/cfRNA in Clinical Trials

7.4 Pharma Companies Studying CTCs or cfDNA/cfRNA in Clinical Trials

Figure 7.4. Pharma Companies Progresssing Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA
Table 7.4. Pharma Companies Progresssing Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA
Figure 7.5. CTCs Vs. cfDNA/cfRNA in Clinical Trials by Pharma Companies
Table 7.5. CTCs Vs. cfDNA/cfRNA in Clinical Trials by Pharma Companies

7.5 Cancer Types

Figure 7.6. Pharma Companies Progresssing Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, by Cancer Type
Table 7.6. Pharma Companies Progresssing Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, by Cancer Type
Figure 7.7. CTCs Vs. cfDNA/cfRNA in Clinical Trials by Cancer Type
Table 7.7. CTCs Vs. cfDNA/cfRNA in Clinical Trials by Cancer Type

7.6 Approved Drugs and CTCs or cfDNA/cfRNA Clinical Trials

Figure 7.8. Approved Drugs in Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, 2012-2015
Table 7.8. Approved Drugs in Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, 2012-2015

7.7 CTC or cfDNA/cfRNA by Clinical Trial Phase

Figure 7.9. Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, by Pharma Company and Clinical Trials Phase
Table 7.9. Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, by Pharma Company and Clinical Trials Phase

CHAPTER 8 DISCUSSION (p343)

8.1 Discussion